SFX by Ex Libris Inc.

Title:	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
Source:	Cancer [0008-543X] Badrising, Sushil yr:2013

Basic

Full text

Full text available via Wiley Online Library Free Backfiles

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Azad, A. "A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer." The Prostate 74.15 (2014): 1544-1550.
description	2.	Bae. "Clinical significance of serum CA-125 in Korean females with ascites." Yonsei Medical Journal 54.5 (2013): 1241-1247.
description	3.	Caffo, O. "Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer." Urology 82.5 (2013): 1090-1093.
description	4.	Alva, A. "Intermittent Androgen Deprivation Therapy in Advanced Prostate Cancer." Current treatment options in oncology 15.1 (2014): 1-10.
description	5.	Oudard, S. "TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer." Future oncology 7.4 (2011): 497-506.
description	6.	de Bono, Johann S. "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial." Lancet 376.(De Bono) Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom (2010): 1147-54.
description	7.	太田, 正之. "【ここまで進んだ鏡視下手術】肥満症." 臨牀と研究 99.6 (2022): 744-748.
description	8.	Lorente, D.. "Sequencing of agents in castration-resistant prostate cancer." Lancet oncology 16.6 (2015): -92.
description	9.	Mangir, N. "Quimioterapia basada en docetaxel en el tratamiento de pacientes con cáncer de prostata resistente a la castración." Actas urológicas españolas 38.8 (2014): 515-522.
description	10.	Aggarwal, R. "Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment." Clinical genitourinary cancer 12.5 (2014): -72.
description	11.	Balagamwala. "Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma: Clinical article." Journal of neurosurgery. Spine 17.6 (2012): 556-564.
description	12.	Baetz. "A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours." Investigational new drugs 25.3 (2007): 217-225.
description	13.	Gauthier, H. "Abiraterone acetate withdrawal syndrome: does it exist?" Case reports in oncology 5.2 (2012): 385-7.
description	14.	Barnier, C. "Desorption kinetics of PAHs from aged industrial soils for availability assessment." Science of the total environment 470 (2014): 639-645.
description	15.	Pezaro, Carmel J. "Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents." European urology 66.3 (2013): 459-65.
description	16.	Mateo, J. "Novel drugs targeting the androgen receptor pathway in prostate cancer." Cancer and Metastasis Reviews 33.2 (2014): 1-13.
description	17.	Loriot, Y. "Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)." Annals of oncology 24.7 (2013): 1807-1812.
description	18.	Sartor, A Oliver O. "Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space." Journal of Hematology & Oncology 4.1 (2011): 18-18.
description	19.	Phair, I C C. "The conservative management of volar avulsion fractures of the P.I.P. joint." Journal of hand surgery. British volume 14.2 (1989): 168-170.
description	20.	de Wit, R. "Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tr." Journal of clinical oncology 19.6 (2001): 1629-40.